GLP-1
Galapagos NV announce a restructuring of their cystic fibrosis (CF) alliance; AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF.
Galapagos NV announces topline interim results of Part 1 of the FALCON trial in cystic fibrosis (CF).
Cash position of EUR 44.2 million as of September 30, 2018
What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio instead of walking away.
LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.
ADOCIA announces that Eli Lilly and Company (“Lilly”) filed a complaint against Adocia in the United States District Court of the Southern District of Indiana on October 9th, 2018.
Key milestones reached for GMP manufacturing of HDP-101
LGC Axolabs announces a significant investment at its site at Kulmbach, Germany, to expand the capacity of its specialist therapeutic oligonucleotide development solutions business and create a new GMP analytical capability.
Almac Group is delighted to announce its global analytical services capabilities spanning UK, Europe and North America.
LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of Berry and Associates, premier supplier of specialty oligo reagents.
PRESS RELEASES